Trastuzumab: new indication. Adjuvant breast cancer treatment for a minority

Prescrire Int. 2007 Jun;16(89):106.

Abstract

An improvement in survival time, but cardiotoxicity remains a concern.

MeSH terms

  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use*
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / genetics
  • Breast Neoplasms / mortality
  • Chemotherapy, Adjuvant
  • Female
  • France
  • Humans
  • Receptor, ErbB-2 / genetics

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Receptor, ErbB-2